Company Description
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally.
It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson’s disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer’s disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.
It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name.
The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.
Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 2015 |
| IPO Date | Dec 3, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Christer Rosen |
Contact Details
Address: 1001 North US Highway 1, Suite 504 Jupiter, Florida 33477 United States | |
| Phone | 561 406 6154 |
| Website | jupiterneurosciences.com |
Stock Details
| Ticker Symbol | JUNS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1679628 |
| ISIN Number | US48208B2034 |
| Employer ID | 47-4828381 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christer Rosen | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Alison D. Silva MA, MS | President, Chief Business Officer and Director |
| Dr. Marshall Hayward Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Alexander Rosen | Co-Founder and Chief Administrative Officer |
| Saleem Elmasri CPA | Chief Financial Officer and Secretary |
| Dr. Claes Wahlestedt M.D., Ph.D. | Co-Founder, Co-Chairman of Scientific Advisory Board and Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 424B3 | Prospectus |
| Jun 5, 2026 | 8-K | Current Report |
| May 21, 2026 | 424B3 | Prospectus |
| May 21, 2026 | 424B3 | Prospectus |
| May 21, 2026 | 8-K | Current Report |
| May 21, 2026 | 424B5 | Filing |
| May 20, 2026 | 424B3 | Prospectus |
| May 20, 2026 | 8-K | Current Report |
| May 14, 2026 | 424B3 | Prospectus |
| May 14, 2026 | 10-Q | Quarterly Report |